Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
Month: March 2023
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
The BIIB080 Phase 1b clinical study is the first to show a reduction of this…
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
The BIIB080 Phase 1b clinical study is the first to show a reduction of this…
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…
BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…